Mysuru: A new study conducted by scientists at JSS Medical College, JSS Academy of Higher Education and Research (JSSAHER), ...

The stock options have an exercise price of $1.27 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of ...

Idiopathic pulmonary fibrosis is a potentially fatal disease currently without treatment, in which lung tissue develops scarring and becomes stiff, making breathing increasingly difficult over time.

A research group from the National Cancer Research Center (CNIO) has found that an alteration in the POT1 gene prevents lung tissue from regenerating, which over time makes breathing difficult. The ...

Idiopathic pulmonary fibrosis is a potentially fatal disease currently without treatment, in which lung tissue develops scarring and becomes stiff ...

Visionary Holdings (GV) entered into a strategic partnership with Jiangsu Yike Regenerative Medicine. The two parties will combine their ...

(GLOBE NEWSWIRE) -- (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an ...

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo ...

Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer.

The biotech is now running a Phase II expansion study to better evaluate the long-term benefits of ateganosine in third-line ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies ...

Estimated median progression free survival (PFS) in third-line treatment (180 mg dose) was 5.6 months. The comparable PFS threshold in standard of care treatments is 2.5 months 1.